Going beyond our current areas of expertise, we are investigating the therapeutic potential of new clinical indications and demonstrate further evidence of Stallergenes Greer AIT treatments beyond clinical trials.

Clinical trials

Stallergenes Greer’s treatments are supported by many clinical studies to evaluate their safety and efficacy, and to produce high-quality data for decision-making. 

• Staloral^®: 30 double-blind, placebo-controlled studies; 3,200 patients enrolled in total. The studies aimed to evaluate the tolerability and efficacy of Staloral® for the treatment of allergic rhinitis and asthma in the short- and long-term, as well as after stopping the treatment, in children and adults. 
• Oralair^® / AitGrys®: full clinical development; more than 2,500 patients enrolled. The studies evaluated the tolerability and efficacy of Oralair® after one month, in the short- and long-term and after the treatment has ended. 
• Actair^® / Orylmyte^® / Aitmyte^® : full clinical development; more than 3,500 patients enrolled. The studies evaluated the tolerability and efficacy of Actair® after four months, in the short-term as well as one year after the treatment has ended. 
• Palforzia^®: full clinical development; 9 clinical trials and more than 1350 patients enrolled. The studies evaluated the efficacy and safety of Palforzia to increase the tolerated dose of peanut (desensitisation) in subjects allergic to peanut, with the therapeutic objective of protecting them against accidental exposure. 

Real-world studies

A real-world  studies include large patient populations better reflecting patient profiles in real life. Hence, they provide useful data to optimise AIT prescription and clinical performance. Among the real-world studies conducted by the Group, the most recent ones are:

• BREATH: evaluated the benefits of AIT based on the decrease of symptomatic treatment dispensation for allergic rhinitis and asthma for patients with respiratory allergies.
• EfficAPSI: the largest retrospective real-world, longitudinal cohort study regarding sublingual liquid AIT. Its objective was to evaluate the real-life impact of sublingual liquid AIT on the onset and worsening of asthma in patients with allergic rhinitis. This study included more than 100,000 patients in France with allergic rhinitis, with or without asthma, treated with sublingual liquid AIT and symptomatic drugs, and more than 330,000 patients with allergic rhinitis, with or without asthma, treated with symptomatic drugs only.
• MaDo: retrospectively analysed the needs, reasons, modalities and impacts of AIT dose adjustment.
• PRACTIS: evaluated the benefits of sublingual AIT in current practice according to the different methods of use and the type of allergen.
• CORAP: evaluated the impact of Covid-19 as perceived by allergic patients treated with AIT before and during the pandemic.

Palforzia®: © 2023, Société des Produits Nestlé S.A. ou ses filiales